Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00572052 · ClinicalTrials.gov registry record · Phase 4
Comparison of Glycemic Control Achieved With 2 Different Needles
A Phase 4 study of Diabetes Mellitus, Type 2 and Diabetes, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 4
- Development phase
- 62
- Enrollment target
- 5
- Study locations
NCT00572052: Completed Phase 4 study of Diabetes Mellitus, Type 2 and Diabetes, sponsored by Novo Nordisk A/S.
NCT00572052 is a Phase 4 study of Diabetes Mellitus, Type 2 and Diabetes that has completed, run by Novo Nordisk A/S. The registered enrollment target is 62 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00572052, a Phase 4 study of Diabetes Mellitus, Type 2 and Diabetes, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 62 participants
- Enrollment target
- 5
- Study locations
Study Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate if a 31 gauge x 6 mm needle will provide comparable blood glucose control to the 29 gauge x 12.7 mm needle in obese subjects with diabetes.
Conditions Studied
Interventions
- DEVICE NovoFine® needle 6 mm
- DEVICE Ultra-Fine needle 12.7 mm
Study Locations (5)
New Jersey
- Novo Nordisk Investigational Site - Berlin
- Novo Nordisk Investigational Site - Lawrenceville
California
- Novo Nordisk Investigational Site - Walnut Creek
Ohio
- Novo Nordisk Investigational Site - Kettering
Texas
- Novo Nordisk Investigational Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2002-12 |
| Est. Completion | 2003-10 |
| Phase | Phase 4 |
What the finished NCT00572052 record still lists
NCT00572052 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower).
The record links to 4 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which NovoFine® needle 6 mm is the first listed.
NCT00572052 lists 5 locations in 4 states (New Jersey, California, Ohio).
Frequently Asked Questions
What is clinical trial NCT00572052 about?
NCT00572052 is a clinical study titled "Comparison of Glycemic Control Achieved With 2 Different Needles". This trial is conducted in the United States of America (USA). The aim of this trial is to investigate if a 31 gauge x 6 mm needle will provide comparable blood glucose control to the 29 gauge x 12.7 mm needle in obese subjects with diabetes.
What is the current status of trial NCT00572052?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 62 participants. The study started on 2002-12. Estimated completion is 2003-10.
What conditions does trial NCT00572052 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes, Diabetes Mellitus, Type 1, Delivery Systems.
What interventions are being tested in trial NCT00572052?
The interventions under investigation include: NovoFine® needle 6 mm (DEVICE), Ultra-Fine needle 12.7 mm (DEVICE).
Who is sponsoring clinical trial NCT00572052?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00572052 being conducted?
This trial has 5 study locations across California, New Jersey, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00572052's enrollment target sits among peer trials
62 240th of 348 higher than 106 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes
RECRUITING · Phase 4
-
Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes
RECRUITING · Phase 4
-
Effect of Continuing Versus Holding Metformin During Hospitalizations.
RECRUITING · Phase 4
-
Surgical or Medical Treatment
ACTIVE NOT RECRUITING · Phase 4
-
Afrezza® Dosing Optimization Study
COMPLETED · Phase 4
-
Effect of Thiazolidinedione Treatment Vascular Risk Markers
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia